Gadodiamide

Follow your doctor's instructions about any restrictions on food, beverages, or activity.

This medication can harm the kidneys in certain people, and this effect may be increased if you also use other medicines harmful to the kidneys. Many other drugs (including some over-the-counter medicines) can harm your kidneys. You may need dose adjustments or special tests if you have recently used any of these medications, such as:

• lithium (Eskalith, Lithobid);
• methotrexate (Rheumatrex, Trexall);
• pain or arthritis medicines such as aspirin (Anacin, Excedrin), acetaminophen (Tylenol), ibuprofen (Advil, Motrin), naproxen (Aleve, Naprosyn, Naprelan, Treximet), celecoxib (Celebrex), diclofenac (Arthrotec, Cambia, Cataflam, Voltaren, Flector Patch, Pennsaid, Solareze), indomethacin (Indocin), meloxicam (Mobic), and others;
• medicines used to treat ulcerative colitis, such as mesalamine (Pentasa) or sulfasalazine (Azulfidine);
• medicines used to prevent organ transplant rejection, such as cyclosporine (Gengraf, Neoral, Sandimmune), sirolimus (Rapamune) or tacrolimus (Prograf);
• IV antibiotics such as amphotericin B (Amphotec, AmBisome, Abelcet), amikacin (Amikin), bacitracin (Baci IM), capreomycin (Capastat), gentamicin (Garamycin), kanamycin (Kantrex), streptomycin, or vancomycin (Vancocin, Vancoled);
• antiviral medicines such as acyclovir (Zovirax), adefovir (Hepsera), cidofovir (Vistide), foscarnet (Foscavir), ganciclovir (Cytovene), valacyclovir (Valtrex), or valganciclovir (Valcyte); or
• cancer medicine such as aldesleukin (Proleukin), carmustine (BiCNU, Gliadel), cisplatin (Platinol), ifosfamide (Ifex), oxaliplatin (Eloxatin), streptozocin (Zanosar), or tretinoin (Vesanoid).

There may be other drugs that can affect gadodiamide. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.

Take gadodiamide exactly as prescribed by your doctor. Follow the directions on your prescription label carefully.

The Gadodiamide dose your doctor recommends will be based on the following (use any or all that apply):

• the condition being treated
• other medical conditions you have
• other medications you are taking
• how you respond to this medication
• your weight
• your height
• your age
• your gender

Gadodiamide is available in the following doses:

• Gadodiamide 287 Mg/ml Injectable Solution

• Dotarem
• Gadavist
• Magnevist

• OptiMARK
• ProHance

© Omniscan Patient Information is supplied by Cerner Multum, Inc. and Omniscan Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Gadodiamide is a contrast agent that produces magnetic effects. It is used in combination with magnetic resonance imaging (MRI) to allow blood vessels, organs, and other non-bony tissues to be seen more clearly on the MRI.

Gadodiamide is used to help diagnose certain disorders of the brain and spine (central nervous system), or the stomach and chest areas.

Gadodiamide may also be used for purposes not listed in this medication guide.

Usual Adult Dose for CNS Magnetic Resonance Imaging:

To visualize lesions with abnormal vascularity in the brain, spine, and associated tissues:
0.2 mL/kg (0.1 mmol/kg) administered as a bolus intravenous injection.

Usual Adult Dose for Vascular Magnetic Resonance Imaging:

To facilitate the visualization of lesions with abnormal vascularity within the thoracic, abdominal, pelvic cavities, and the retroperitoneal space:

Kidney: 0.1 mL/kg (0.05 mmol/kg) administered as a bolus intravenous injection.
Intrathoracic, intra-abdominal, and pelvic cavities: 0.2 mL/kg (0.1 mmol/kg) administered as a bolus intravenous injection.

Usual Pediatric Dose for CNS Magnetic Resonance Imaging:

To visualize lesions with abnormal vascularity in the brain, spine, and associated tissues:
2 years and older:
0.2 mL/kg (0.1 mmol/kg) administered as a bolus intravenous injection.

Usual Pediatric Dose for Vascular Magnetic Resonance Imaging:

To facilitate the visualization of lesions with abnormal vascularity within the thoracic, abdominal, pelvic cavities, and the retroperitoneal space:

2 years and older:
Kidney: 0.1 mL/kg (0.05 mmol/kg) administered as a bolus intravenous injection.
Intrathoracic, intra-abdominal, and pelvic cavities: 0.2 mL/kg (0.1 mmol/kg) administered as a bolus intravenous injection.

Applies to gadodiamide: injectable solution

Cardiovascular

Cardiovascular side effects have included cardiac failure, arrhythmia and myocardial infarction. Also reported include vasodilation, flushing, chest pain, deep thrombophlebitis, and rarely, arrhythmia and myocardial infarction resulting in death in patients with ischemic heart disease.[Ref]

Nervous system

Nervous system side effects have included headache, tinnitus, taste loss, taste perversion, and dizziness. Convulsions including grand mal, ataxia, abnormal coordination, paresthesia, tremor, aggravated multiple sclerosis (characterized by sensory and motor disturbances), and aggravated migraine have been reported.[Ref]

Gastrointestinal

Gastrointestinal side effects have included nausea, abdominal pain, diarrhea, eructation, dry mouth, vomiting, and melena.[Ref]

Hypersensitivity

Hypersensitivity side effects have included anaphylactoid reactions (characterized by cardiovascular, respiratory, and cutaneous symptoms).[Ref]

General

General side effects have included fever, hot flushes, rigors, fatigue, malaise, pain, and syncope.[Ref]

Hepatic

Hepatic side effects have included abnormal hepatic function.[Ref]

Respiratory

Respiratory side effects have included rhinitis and dyspnea.[Ref]

Ocular

Ocular side effects have included abnormal vision.[Ref]

Renal

Renal side effects have included acute reversible renal failure.[Ref]

Musculoskeletal

Musculoskeletal side effects have included arthralgia and myalgia.[Ref]

Dermatologic

Dermatologic side effects have included pruritus, rash, erythematous rash, increased sweating, and urticaria.[Ref]

Some side effects of gadodiamide may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.

To visualize lesions with abnormal vascularity in the brain, spine, and associated tissues:
2 years and older:
0.2 mL/kg (0.1 mmol/kg) administered as a bolus intravenous injection.

Data not available

Gadodiamide has been assigned to pregnancy category C by the FDA. Animal studies have revealed evidence of teratogenicity. There are no controlled data in human pregnancy. Gadodiamide is only recommended for use during pregnancy when there are no alternatives and benefit outweighs risk.

There are no data on the excretion of gadodiamide into human milk. The effects in the nursing infant are unknown. The manufacturer recommends that caution be used when administering gadodiamide to nursing women.